Green Plains to Participate in Jefferies Industrials Conference

OMAHA, Neb.--(BUSINESS WIRE)-- Green Plains Inc. (NASDAQ: GPRE) today announced that Todd Becker, President and Chief Executive Officer, will be participating in a fireside chat at the Jefferies Industrials Conference in New York City on Thursday, Sept. 7 at 3 p.m. Eastern time (2 p.m. Central time). Additionally, the company will be participating in meetings with institutional investors during the conference.

Materials used for the conference, the live webcast, as well as the replay, will be available on the Investors page of Green Plains’ website at https://investor.gpreinc.com/events-presentations.

About Green Plains Inc.

Green Plains Inc. (NASDAQ: GPRE) is a leading biorefining company focused on the development and utilization of fermentation, agricultural and biological technologies in the processing of annually renewable crops into sustainable value-added ingredients. This includes the production of cleaner low-carbon biofuels, renewable feedstocks for advanced biofuels and high-purity alcohols for use in cleaners and disinfectants. Green Plains is an innovative producer of Ultra-High Protein and novel ingredients for animal and aquaculture diets to help satisfy a growing global appetite for sustainable protein. The Company also owns a 48.8% limited partner interest and a 2.0% general partner interest in Green Plains Partners LP. For more information, visit www.gpreinc.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230828905631/en/

Investors: Phil Boggs | Executive Vice President, Investor Relations | 402.884.8700 | [email protected]
Media: Lisa Gibson | Communications Manager | 402.952.4971 | [email protected]

Source: Green Plains Inc.

You May Also Be Interested In

• Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 S
• Sonesitatug vedotin reduced the risk of death by 42% in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers in CLARITY-Gastric01
• Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026